Acadia Pharmaceuticals INC Form 4 insider transactions

Mark C. Schneyer, EVP, CHIEF FINANCIAL OFFICER of Acadia Pharmaceuticals Inc, sold 20,141 shares of common stock on August 5, 2026.

Elizabeth H.Z. Thompson, EVP, Head of Research & Dev of Acadia Pharmaceuticals Inc, sold 16,558 shares of common stock on July 29, 2026.

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reported a sale of common stock under a Rule 10b5-1 trading plan.

Baker Bros. Advisors LP, a significant holder, has reported changes in beneficial ownership of Acadia Pharmaceuticals Inc. common stock and stock options.

Director Edmund Harrigan acquired 8,107 shares of Acadia Pharmaceuticals common stock through the vesting of restricted stock units.

Director Adora Ndu exercised restricted stock units and received new equity grants as part of Acadia Pharmaceuticals' annual compensation cycle.

Director Laura Brege exercised restricted stock units and received new equity grants in Acadia Pharmaceuticals.

Director Jonathan Poole acquired common stock through restricted stock unit vesting and received new equity grants.

Director Elizabeth A. Garofalo reported the vesting of restricted stock units and the acquisition of new equity awards in Acadia Pharmaceuticals.

Acadia Pharmaceuticals director James M. Daly reported the vesting of restricted stock units and the acquisition of new stock options.

Principal Accounting Officer James Kihara sold 5,401 shares of Acadia Pharmaceuticals common stock on May 26, 2026.

Principal Accounting Officer James Kihara reported the vesting of restricted stock units and a subsequent sale to cover tax obligations.

Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, sold 3,506 shares of common stock to cover tax obligations following the vesting of 6,815 restricted stock units.

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals Inc., reported transactions involving the sale of company stock.

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reported transactions involving the sale of common stock.

ACADIA Pharmaceuticals CEO Catherine Owen Adams reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Jennifer J. Rhodes, EVP, Chief Legal Officer of ACADIA Pharmaceuticals, reported the vesting of 7,515 restricted stock units and a subsequent sale of 3,844 shares to cover tax obligations.

An Acadia Pharmaceuticals executive reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Acadia Pharmaceuticals' Principal Accounting Officer, James Kihara, reported the vesting of restricted stock units and subsequent mandatory sales to cover tax obligations.

Acadia Pharmaceuticals' CFO, Mark C. Schneyer, reported the vesting of restricted stock units and subsequent mandatory sales to cover tax obligations.

Acadia Pharmaceuticals Director Jonathan Poole received new stock options and restricted stock units as part of his compensation.

ACADIA Pharmaceuticals' EVP, Chief Legal Officer, Jennifer J. Rhodes, exercised restricted stock units and subsequently sold a portion of the acquired common stock to cover tax obligations.

Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, reported the acquisition of common stock through RSU vesting and an employee stock purchase plan, alongside a sale to cover tax obligations.

Acadia Pharmaceuticals' Principal Accounting Officer, James Kihara, sold shares to cover tax obligations following restricted stock unit vesting.

Acadia Pharmaceuticals Director James M. Daly sold 30,000 shares of common stock for approximately $22.37 per share in a pre-scheduled transaction.

Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, reported the acquisition of shares from performance unit vesting and a subsequent sale to cover tax obligations.

Acadia Pharmaceuticals director Elizabeth A. Garofalo sold 1,600 shares of common stock for approximately $25.98 per share in a pre-planned transaction.

Acadia Pharmaceuticals' CFO, Mark C. Schneyer, sold 22,000 shares of common stock for approximately $554,000 under a pre-arranged trading plan.

Laura Brege, a Director at ACADIA Pharmaceuticals Inc., reported the sale of 14,446 shares of the company's common stock at a weighted average price of $21.78 per share.

Acadia Pharmaceuticals Inc. Director Daniel B. Soland reported the vesting of restricted stock units and the grant of new stock options and restricted stock units, increasing his beneficial ownership of common stock.